vs

Side-by-side financial comparison of Outdoor Holding Co (POWW) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Outdoor Holding Co is the larger business by last-quarter revenue ($13.4M vs $12.5M, roughly 1.1× Avidity Biosciences, Inc.). Outdoor Holding Co runs the higher net margin — 16.7% vs -1398.3%, a 1415.0% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -54.1%). Outdoor Holding Co produced more free cash flow last quarter ($5.0M vs $-156.9M).

Vista Outdoor Inc. was an American designer, manufacturer, and marketer that operated in two segments: shooting sports and outdoor products. It was a "house of brands" with more than 40 labels and subsidiaries.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

POWW vs RNA — Head-to-Head

Bigger by revenue
POWW
POWW
1.1× larger
POWW
$13.4M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+488.1% gap
RNA
434.0%
-54.1%
POWW
Higher net margin
POWW
POWW
1415.0% more per $
POWW
16.7%
-1398.3%
RNA
More free cash flow
POWW
POWW
$161.9M more FCF
POWW
$5.0M
$-156.9M
RNA

Income Statement — Q3 FY2026 vs Q3 FY2025

Metric
POWW
POWW
RNA
RNA
Revenue
$13.4M
$12.5M
Net Profit
$2.2M
$-174.4M
Gross Margin
87.1%
Operating Margin
14.7%
-1513.5%
Net Margin
16.7%
-1398.3%
Revenue YoY
-54.1%
434.0%
Net Profit YoY
108.5%
-117.0%
EPS (diluted)
$0.01
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
POWW
POWW
RNA
RNA
Q4 25
$13.4M
Q3 25
$12.0M
$12.5M
Q2 25
$11.9M
$3.8M
Q1 25
$12.6M
$1.6M
Q4 24
$12.5M
$3.0M
Q3 24
$12.0M
$2.3M
Q2 24
$12.3M
$2.0M
Q1 24
$-50.7M
$3.5M
Net Profit
POWW
POWW
RNA
RNA
Q4 25
$2.2M
Q3 25
$1.4M
$-174.4M
Q2 25
$-6.5M
$-157.3M
Q1 25
$-77.5M
$-115.8M
Q4 24
$-26.1M
$-102.3M
Q3 24
$-12.4M
$-80.4M
Q2 24
$-14.8M
$-70.8M
Q1 24
$-5.2M
$-68.9M
Gross Margin
POWW
POWW
RNA
RNA
Q4 25
87.1%
Q3 25
87.1%
Q2 25
87.2%
Q1 25
87.5%
Q4 24
87.4%
Q3 24
86.9%
Q2 24
85.8%
Q1 24
Operating Margin
POWW
POWW
RNA
RNA
Q4 25
14.7%
Q3 25
5.9%
-1513.5%
Q2 25
-50.7%
-4448.7%
Q1 25
-213.6%
-8360.9%
Q4 24
-163.8%
-4069.6%
Q3 24
-50.3%
-4200.9%
Q2 24
-50.8%
-4040.4%
Q1 24
-2178.6%
Net Margin
POWW
POWW
RNA
RNA
Q4 25
16.7%
Q3 25
11.7%
-1398.3%
Q2 25
-54.5%
-4089.3%
Q1 25
-614.5%
-7360.0%
Q4 24
-208.7%
-3439.5%
Q3 24
-103.7%
-3441.7%
Q2 24
-120.2%
-3461.8%
Q1 24
10.3%
-1943.4%
EPS (diluted)
POWW
POWW
RNA
RNA
Q4 25
$0.01
Q3 25
$0.01
$-1.27
Q2 25
$-0.06
$-1.21
Q1 25
$-0.67
$-0.90
Q4 24
$-0.23
$-0.80
Q3 24
$-0.11
$-0.65
Q2 24
$-0.13
$-0.65
Q1 24
$-0.05
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
POWW
POWW
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$69.9M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$237.3M
$1.9B
Total Assets
$271.7M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
POWW
POWW
RNA
RNA
Q4 25
$69.9M
Q3 25
$65.7M
$350.2M
Q2 25
$63.4M
$243.9M
Q1 25
$30.2M
$254.2M
Q4 24
$31.9M
$219.9M
Q3 24
$33.5M
$370.2M
Q2 24
$50.8M
$575.8M
Q1 24
$55.6M
$471.4M
Stockholders' Equity
POWW
POWW
RNA
RNA
Q4 25
$237.3M
Q3 25
$235.4M
$1.9B
Q2 25
$222.5M
$1.2B
Q1 25
$222.0M
$1.3B
Q4 24
$299.6M
$1.4B
Q3 24
$325.6M
$1.5B
Q2 24
$342.5M
$1.2B
Q1 24
$358.0M
$830.9M
Total Assets
POWW
POWW
RNA
RNA
Q4 25
$271.7M
Q3 25
$270.3M
$2.1B
Q2 25
$269.5M
$1.4B
Q1 25
$297.3M
$1.5B
Q4 24
$355.4M
$1.6B
Q3 24
$368.9M
$1.6B
Q2 24
$398.6M
$1.3B
Q1 24
$403.0M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
POWW
POWW
RNA
RNA
Operating Cash FlowLast quarter
$5.7M
$-156.2M
Free Cash FlowOCF − Capex
$5.0M
$-156.9M
FCF MarginFCF / Revenue
37.6%
-1257.6%
Capex IntensityCapex / Revenue
4.8%
5.7%
Cash ConversionOCF / Net Profit
2.55×
TTM Free Cash FlowTrailing 4 quarters
$-2.3M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
POWW
POWW
RNA
RNA
Q4 25
$5.7M
Q3 25
$3.2M
$-156.2M
Q2 25
$-6.7M
$-199.7M
Q1 25
$-1.5M
$-124.8M
Q4 24
$1.3M
$-99.9M
Q3 24
$-9.3M
$-65.6M
Q2 24
$-547.5K
$-65.0M
Q1 24
$4.3M
$-70.4M
Free Cash Flow
POWW
POWW
RNA
RNA
Q4 25
$5.0M
Q3 25
$2.5M
$-156.9M
Q2 25
$-7.6M
$-203.0M
Q1 25
$-2.3M
$-128.6M
Q4 24
$720.3K
$-103.8M
Q3 24
$-10.6M
$-67.3M
Q2 24
$-1.3M
$-65.5M
Q1 24
$1.4M
$-71.3M
FCF Margin
POWW
POWW
RNA
RNA
Q4 25
37.6%
Q3 25
21.0%
-1257.6%
Q2 25
-63.8%
-5277.1%
Q1 25
-18.6%
-8174.3%
Q4 24
5.8%
-3491.0%
Q3 24
-88.3%
-2881.8%
Q2 24
-11.0%
-3204.6%
Q1 24
-2.8%
-2012.3%
Capex Intensity
POWW
POWW
RNA
RNA
Q4 25
4.8%
Q3 25
5.8%
5.7%
Q2 25
7.5%
86.9%
Q1 25
6.5%
238.6%
Q4 24
4.4%
131.7%
Q3 24
10.4%
72.9%
Q2 24
6.5%
26.0%
Q1 24
-5.7%
25.8%
Cash Conversion
POWW
POWW
RNA
RNA
Q4 25
2.55×
Q3 25
2.29×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons